Tempest Therapeutics, Inc. (TPST)

The investment case for this biotech firm is effectively extinguished by a catastrophic multi-year price collapse. While the company recently generated some cash from warrant exercises and private placements, the market has punished the stock relentlessly, erasing over 99% of its value since 2016. The most damning indicator is the trajectory: eight out of the last nine years saw significant losses, with the most recent year also posting a sharp decline. This persistent downward trend suggests the market views the current business model as fundamentally broken or insufficient to sustain operations, regardless of the single positive year in 2024. Financially, the picture is dire; the company is burning through cash at an alarming rate, with operating cash flow and free cash flow both deeply negative, while carrying debt that dwarfs its meager cash reserves. The balance sheet is fragile, with a current ratio well below 1.0, indicating an imminent liquidity crisis where liabilities exceed immediate assets. There is no dividend to provide any income cushion, and the lack of analyst coverage combined with a negative forward P/E confirms that earnings are not expected to turn positive soon. Although the stock price has shown a brief, volatile uptick in the last two weeks, this appears to be a dead-cat bounce rather than a reversal, given the overwhelming weight of the long-term decline and the deteriorating fundamentals.